VaxGen: Are There Hints of Race-Based Effects?
By Patricia Kahn
Philip Berman, developer of VaxGen’s gp120-based AIDSVAX® vaccine, gave a much-anticipated talk on the outcome of the company’s North America/Europe Phase III trial.
By Patricia Kahn
Philip Berman, developer of VaxGen’s gp120-based AIDSVAX® vaccine, gave a much-anticipated talk on the outcome of the company’s North America/Europe Phase III trial.